Advertisement

Control of Nuclear Function in Chromaffin Cells by Persistent Activation of Nicotinic Receptors

  • E. Costa
  • D. M. Chuang
  • A. Guidotti
  • R. Hollenbeck
Part of the Advances in Behavioral Biology book series (ABBI, volume 24)

Abstract

The membrane of chromaffin cells contains nicotinic and muscarinic receptors which are innervated by cholinergic axons — the only neurites reaching the adrenal gland. Persistent activation of nicotinic receptors is associated with an increase in the 3′, 5′-cyclic adenosine monophosphate (cAMP) (19) content of adrenal medulla, whereas the stimulation of muscarinic receptors causes an increase in the 3′, 5′-cyclic guanosine monophosphate (cGMP) content (21). The data reported in Fig. 1 show that carbamylcholine, a mixed agonist of nicotinic and muscarinic receptors increases the cAMP and cGMP content of adrenal medulla. In addition, Fig. 1 shows that hexamethonium blocks the increase of cAMP but not that of cGMP elicited by carbamylcholine, In contrast, atropine blocks the increase in cGMP but not that in cAMP elicited by the cholinergic receptor agonist.

Keywords

Tyrosine Hydroxylase Catalytic Subunit Protein Kinase Activity CHROMAFFIN Cell Nicotinic Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Appleman, M. M., Thompson, W.J. and Russell, J. R. (1973): In: Advances in Cyclic Nucleotide Research, Vol.3 (Eds.) P. Greengard and G.A. Robison, Raven Press, New York, pp. 65–98.Google Scholar
  2. 2.
    Axelrod, J. (1971): Science 173:598–606.PubMedCrossRefGoogle Scholar
  3. 3.
    Castagna, M., Palmer, W.K. and Walsh, D.A. (1975): Eur. J. Pharmacol. 55:193–199.Google Scholar
  4. 4.
    Cheung, W. Y. (1970): Biochem. Biophys. Res. Commun. 38:533–538.PubMedCrossRefGoogle Scholar
  5. 5.
    Cheung, W. Y., Ling, Y. M., Liu, Y. P. and Smoake, J. A. (1975): In: Cyclic Nucleotides in Disease. (Ed.) B. Weiss, University Park Press, Baltimore, pp. 321–350.Google Scholar
  6. 6.
    Chuang, D.M. and Costa, E. (1976): Molec. Pharmacol. 12:514–518.Google Scholar
  7. 7.
    Chuang, D.M. and Costa, E. (1974): Proc. Nat. Acad. Sci. USA 71: 4570–4574.PubMedCrossRefGoogle Scholar
  8. 8.
    Chuang, D.M., Hollenbeck, R. and Costa, E. (1976): Science 193: 60–63.PubMedCrossRefGoogle Scholar
  9. 9.
    Corbin, J.D., Soderling, T.R. and Park, C.R. (1973): J. Biol. Chem. 248:1813–1821.PubMedGoogle Scholar
  10. 10.
    Costa, E., Chuang, D.M., Guidotti, A. and Uzunov, P. (1975): In: Chemical Tools in Catecholamine Research II. (Eds.) O. Almgren, A. Carlsson and J. Engel, North Holland Publ. Co., Amsterdam, pp.283–292.Google Scholar
  11. 11.
    Costa, E. and Guidotti, A. (1973): In: New Concepts in Neurotransmitter Regulation. (Ed.) A. J. Mandell, Plenum Press, New York, pp.135–152.CrossRefGoogle Scholar
  12. 12.
    Costa, E., Guidotti, A. and Hanbauer, I. (1975): In: Cyclic Nucleotides in Disease. (Ed.) B. Weiss, University Park Press, Baltimore, pp. 167–186.Google Scholar
  13. 13.
    Costa, E., Guidotti, A. and Hanbauer, I. (1975): In: Neuropsycho-pharmacology. (Eds.) J.R. Boissier, H. Hippius and P. Pichot, Excerpta Medica, Amsterdam, pp. 952–955.Google Scholar
  14. 14.
    Costa, E., Guidotti, A. and Hanbauer, I. (1974): Life Sci. 14:1169–1188.PubMedCrossRefGoogle Scholar
  15. 15.
    Costa, E., Guidotti, A. and Kurosawa, A. (1975): In: Biological Membranes: Neurochemistry. Vol.41, (Ed.) Y. Eaoul, North Holland Publ. Co., Amsterdam, pp. 137–149.Google Scholar
  16. 16.
    Costa, E., Kurosawa, A. and Guidotti, A. (1976): Proc. Nat. Acad. Sci. USA 73: 10 58–1062.Google Scholar
  17. 17.
    Gnegy, M., Costa, E. and Uzunov, P. (1976): Proc. Nat. Acad. Sci. USA 73:352–355.PubMedCrossRefGoogle Scholar
  18. 18.
    Gnegy, M., Uzunov, P. and Costa, E. (1976): Proc. Nat. Acad. Sci. USA 73:3887–3890.PubMedCrossRefGoogle Scholar
  19. 19.
    Guidotti, A. and Costa, E. (1974): J. Pharmacol. Exp. Ther. 189: 665–675.PubMedGoogle Scholar
  20. 20.
    Guidotti, A. and Costa, E. (1974): N.-S. Arch. Pharmacol. 282: 217–221.CrossRefGoogle Scholar
  21. 21.
    Guidotti, A., Hanbauer, I. and Costa, E. (1975): In: Advances in Cyclic Nucleotide Research. Vol.5. (Eds.) G.I. Drummond, P. Greengard and G. A. Robison, Raven Press, New York, pp. 619–639.Google Scholar
  22. 22.
    Guidotti, A., Kurosawa, A., Chuang, D.M. and Costa, E. (1975): Proc. Nat. Acad. Sci. USA 72:1152–1156.PubMedCrossRefGoogle Scholar
  23. 23.
    Guidotti, A., Kurosawa, A. and Costa, E. (1976): N.-S. Arch. Pharmacol. 295:135–140.CrossRefGoogle Scholar
  24. 24.
    Guidotti, A., Mao, C. C. and Costa, E. (1974): In: Advances in Cytopharmacology. (Eds.) B. Ceccarelli, F. Clementi, and J. Meldolesi, Raven Press, New York, pp. 39–46.Google Scholar
  25. 25.
    Guidotti, A., Mao, C. C. and Costa, E. (1973): In: Frontiers in Catecholamine Research. (Eds.) E. Usdin and S. Snyder, Pergamon Press, Oxford, pp. 231–236.Google Scholar
  26. 26.
    Guidotti, A., Zivkovic, B., Pfeiffer, R. and Costa, E. (1973): N.-S. Arch. Pharmacol. 278:195–206.CrossRefGoogle Scholar
  27. 27.
    Hanbauer, I. and Guidotti, A. (1975): N.-S. Arch. Pharmacol. 287: 213–217.CrossRefGoogle Scholar
  28. 28.
    Hanbauer, I., Guidotti, A. and Costa, E. (1975): In: Neuropsychopharmacology. (Eds.) J. Boissier, H. Hippius and P. Pichot, Excerpta Medica Fdn., Amsterdam, pp. 932–941.Google Scholar
  29. 29.
    Joh, T.H., Geghman, C. and Reis, D. (1973): Proc. Nat. Acad. Sci. USA 70:2767–2771.PubMedCrossRefGoogle Scholar
  30. 30.
    Jungmann, R. A., Lee, S. G. and DeAngelo, A.B. (1975): In: Advances in Cyclic Nucleotide Research. Vol. 5. (Eds.) G.I. Drummond, P. Greengard and G. A. Robison, Raven Press, New York, pp. 281–306.Google Scholar
  31. 31.
    Jungmann, R.A. and Schweppe, J.S. (1972): J. Biol. Chem. 247: 5535–5542.PubMedGoogle Scholar
  32. 32.
    Keely, S.L. Jr., Corbin, J.D. and Park, C.R. (1975): Proc. Nat. Acad. Sci. USA 72:1501–1504.PubMedCrossRefGoogle Scholar
  33. 33.
    Kurosawa, A., Guidotti, A. and Costa, E. (1976): Molec. Pharmacol. 12:420–432.Google Scholar
  34. 34.
    Kurosawa, A., Guidotti, A. and Costa, E. (1976): Science 193:691–693.PubMedCrossRefGoogle Scholar
  35. 35.
    Mao, C. C. and Guidotti, A. (1974): Anal. Biochem. 59:63–68.PubMedCrossRefGoogle Scholar
  36. 36.
    Mueller, R.A., Thoenen, H. and Axelrod, J. (1969): Molec. Pharmacol. 5:463–469.Google Scholar
  37. 37.
    Mueller, R.A., Thoenen, H. and Axelrod, J. (1969): Science 163: 468–469.PubMedCrossRefGoogle Scholar
  38. 38.
    Otten, U. and Thoenen, H. (1976): N.-S. Arch. Pharmacol. 293: 105–108.CrossRefGoogle Scholar
  39. 39.
    Salem, R. and DeVellis, J. (1976): Fed. Proc. 35:296.Google Scholar
  40. 40.
    Takai, Y., Nishiyama, K., Yamamura, H. and Nishizuka, Y. (1975): J. Biol. Chem. 250:4690–4695.PubMedGoogle Scholar
  41. 41.
    Thoenen, H., Mueller, R.A. and Axelrod, J. (1969): J. Pharmacol. Exp. Ther. 169:249–254.PubMedGoogle Scholar
  42. 42.
    Thoenen, H., Otten, U. and Oesch, F. (1973): In: Frontiers in Catecholamine Research. (Eds.) E. Usdin and S. Snyder, Pergamon Press, Oxford, pp. 179–186.Google Scholar
  43. 43.
    Uzunov, P., Gnegy, M., Lehne, R., Revuelta, A. and Costa, E. (1976): In: Advances in Biochemical Psychopharmacology. Vol. 15. (Eds.) E. Costa, E. Giacobini and R. Paoletti, Raven Press, New York, pp. 283–302.Google Scholar
  44. 44.
    Uzunov, P., Revuelta, A. and Costa, E. (1975): Molec. Pharmacol. 11:506–510.Google Scholar

Copyright information

© Plenum Press, New York 1978

Authors and Affiliations

  • E. Costa
    • 1
  • D. M. Chuang
    • 1
  • A. Guidotti
    • 1
  • R. Hollenbeck
    • 1
  1. 1.Laboratory of Preclinical Pharmacology, National Institute of Mental HealthSaint Elizabeths HospitalUSA

Personalised recommendations